Interview: Éric Gervais, Executive Vice President, Médunik Canada
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
Médunik Canada is dedicated to developing strong partnerships with non-Canadian pharmaceutical and biopharmaceutical companies that are attempting to optimize the return on investment of their orphan drugs; they need to balance the financial risks and complexities associated to the introduction and distribution of their products on the small-size Canadian market. Through in-licensing partnerships, Médunik Canada offers turn-key operations – ranging from regulatory approval strategy to post-approval activities – to assure the commercial success of the partners’ product development efforts.
Medunik Canada
950, boul. Michèle-Bohec
Blainville (Québec) Canada
J7C 5E2
Tel.: + 1 450 433-4441
Fax: + 1 450 433-2211
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
Sylvie Bertrand, general manager of BSN medical Canada, an Essity company, highlights the value proposition BSN medical’s products bring to Canadian patients in chronic venous insufficiency, diabetic foot ulcers and…
Jean-Philippe Gentès, President, and CEO of the rapidly growing ready-to-use injectable manufacturer Sterinova, shares his ideas on the ‘Made in Canada’ label, innovation in North America and the pros and…
Oliver Technow, president at BioVectra, highlights the company’s recent developments; amongst those a significant investment in a manufacturing site near Halifax. The resulting increase in manufacturing capacity by 40 percent…
Michel Fortin, president and CEO of Prevtec Microbia, a global biotech player founded in Saint-Hyacinthe, outside of Montréal, analyzes the opportunities in the global animal health industry, and how Prevtec…
The government of the French-speaking Canadian province of Québec stands out for undertaking healthcare reforms while appreciating the need to join hands with industry when it comes to the promotion…
David Main, CEO and president of Aquinox Pharmaceuticals Inc., introduces the company he founded in 2006, which now is in the late stages of development of a drug targeting the…
Richard Lajoie shares his main priorities for his tenure as new president of Valeant’s Canadian operations: portfolio rejuvenation through launches of innovative molecules addressing the unmet needs of Canadian patients,…
Dr. David Goodman, CEO of Pharmascience, talks about the strategy for the international expansion of the company, key for which are long-lasting partnerships. He also analyzes the re-organization of the…
Stephen Thompson affirms Baxter’s 80-year commitment to Canada, and describes the benefits of having a local manufacturing presence. He further discusses the company’s latest innovations, notably in renal care and…
Sylvain Chrétien, CEO of Pediapharm, introduces the pediatrics-focused company he founded in 2008, having identified a number of unmet needs in the field. Pediapharm brings products to Canadian patients, in…
Ian Jacobson, CEO of Juno Pharmaceuticals, presents the company’s business model of in-licensing and repurposing generic products. He highlights the successful development of the company’s affiliates in Australia, the UK…
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
See our Cookie Privacy Policy Here
